Skip to content

Study · Systematic review · 2024

3 results

Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.

Masson W, Lobo M, Nogueira JP, Rodriguez-Granillo AM, Barbagelata LE, Siniawski D

Frontiers in cardiovascular medicine5 Jul 2024Cited by 43 (Europe PMC)

PMID39055657 (opens in a new tab)PMCIDPMC11270812 (opens in a new tab)DOI10.3389/fcvm.2024.1379189 (opens in a new tab)PepBankPUB-39055657
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

BackgroundThe anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity. Determining the anti-inflammatory effect of semaglutide was the objective of this systematic review and meta-analysis.MethodsThis meta-analysis was performed according to the PRISMA guidelines. A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs). The primary outcome was CRP index (final CRP/basal CRP). A random-effects model was used.ResultsThirteen randomised clinical trials were considered eligible (n = 26,131). Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD -0.56; 95% CI -0.69 to -0.43, I 2 92%) or the control group (SMD -0.45; 95% CI -0.68 to -0.23, I 2 82%).Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed. The sensitivity analysis showed that the results were robust.ConclusionThe present meta-analysis demonstrated that the use of semaglutide was associated with a reduction in inflammation irrespective of the population evaluated or the treatment regimen used. These findings would explain one of the mechanisms by which semaglutide reduces cardiovascular events.Systematic review registrationPROSPERO [CRD42024500551].
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomised trials, semaglutide was associated with a lower CRP index than placebo.

    In plain wordsIn pooled trials, semaglutide was linked to lower CRP, a marker of inflammation, than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseCRP index versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    SMD
    −0.56 SMD
    semaglutide versus placebo

    Source sentences

    Summary
    Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD -0.56; 95% CI -0.69 to -0.43, I 2 92%)
    2 context sentences
    Summary · context
    A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs).
    Summary · context
    Thirteen randomised clinical trials were considered eligible (n = 26,131).
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomised trials, semaglutide was associated with a lower CRP index than other glucose-lowering drugs.

    In plain wordsIn pooled trials, semaglutide was linked to lower CRP, a marker of inflammation, than other diabetes drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseCRP index versus control (other glucose-lowering drugs)
    Study

    n: not reported in source

    Comparator
    Control group (other glucose-lowering drugs)
    Analysis
    Primary
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    SMD
    −0.45 SMD
    semaglutide versus control

    Source sentences

    Summary
    Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD -0.56; 95% CI -0.69 to -0.43, I 2 92%)
    3 context sentences
    Summary · context
    or the control group (SMD -0.45; 95% CI -0.68 to -0.23, I 2 82%)
    Summary · context
    A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs).
    Summary · context
    Thirteen randomised clinical trials were considered eligible (n = 26,131).
  3. 03HumanSystematic reviewEfficacy outcome

    In subgroup analyses by subcutaneous versus oral regimen and by presence of type 2 diabetes, semaglutide was similarly associated with a lower CRP index.

    In plain wordsThe link between semaglutide and lower CRP held for injected and oral semaglutide and for people with or without type 2 diabetes.

    Peptide
    Semaglutide
    Outcome
    DecreaseCRP index by regimen and population subgroups
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed.
    2 context sentences
    Summary · context
    A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs).
    Summary · context
    Thirteen randomised clinical trials were considered eligible (n = 26,131).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.